Improved Potency and Selectivity of an Oncolytic E1ACR2 and E1B19K Deleted Adenoviral Mutant in Prostate and Pancreatic Cancers

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-09-1960
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Minimal RB-responsive E1A Promoter Modification to Attain Potency, Selectivity, and Transgene-Arming Capacity in Oncolytic Adenoviruses

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2010English

The Role of BRCA1 and BRCA2 Mutations in Prostate, Pancreatic and Stomach Cancers

Hereditary Cancer in Clinical Practice
OncologyGenetics
2015English

An Unusual Ligand Coordination Gives Rise to a New Family of Rhodium Metalloinsertors With Improved Selectivity and Potency

Journal of the American Chemical Society
BiochemistryColloidCatalysisChemistrySurface Chemistry
2014English

Oncolytic Potency and Reduced Virus Tumor-Specificity in Oncolytic Virotherapy. A Mathematical Modelling Approach

PLoS ONE
Multidisciplinary
2017English

A Rationally Designed A34R Mutant Oncolytic Poxvirus: Improved Efficacy in Peritoneal Carcinomatosis

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2013English

Hereditary Pancreatic and Hepatobiliary Cancers

International Journal of Surgical Oncology
SurgeryOncology
2011English

Next-Generation Adenoviral Vectors: New and Improved

Gene Therapy
Molecular MedicineGeneticsMolecular Biology
1999English

Activation of TAp73 and Inhibition of TrxR for Improved Cancer Therapy in TP53 Mutant Pancreatic Tumors

Future Science OA
MedicineBiotechnology
2019English

A Simple Method for Constructing E1- And E1/E4-Deleted Recombinant Adenoviral Vectors

Human Gene Therapy
Molecular MedicineGeneticsMolecular Biology
1999English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy